Contraceptive Drugs and Devices Market Size & Growth Forecast 2027–2036, By Segments (Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Contraceptive Drugs and Devices Market size was around USD 34.8 billion in 2026 and is slated to grow at a 5.7% CAGR from 2027 to 2036, surpassing USD 60.58 billion by 2036. The industry revenue for 2027 is assessed at USD 36.47 billion.
Get more details on this report
Request Free Sample ReportContraceptive Drugs and Devices Market Intelligence Snapshot
Regional Market Dynamics
- North America leads due to broad product availability, established prescribing and retail channels, mature healthcare systems, and routine use of short- and long-acting contraceptive options.
- Asia Pacific grows at 6.89% CAGR driven by rising family planning awareness, improving healthcare access, expanding contraceptive availability, and stronger pharmacy and counseling services across urban and semi-urban regions.
Segment Momentum
- Contraceptive Devices hold a 66.54% share due to long-acting, procedure-based effectiveness and reduced reliance on daily adherence, making them widely preferred in routine contraceptive care settings.
- Growth is driven by increasing preference for reliable, convenient, long-acting methods that reduce user dependency and align with evolving healthcare priorities for consistent and low-maintenance contraception.
Market Expansion Drivers
- Rising global focus on reproductive health awareness and family planning programs driving adoption.
- Increasing preference for long-acting reversible contraceptives improving compliance and effectiveness.
- Expanding government-led contraception access initiatives improving affordability in developing regions.
Leading Market Participants
- Top players in the contraceptive drugs and devices market include Bayer AG (Germany), Organon & Co. (United States), Pfizer Inc. (United States), AbbVie Inc. (United States), Viatris Inc. (United States), Johnson & Johnson (United States), Church & Dwight Co., Inc. (United States), Veru Inc. (United States), Cupid Limited (India), Agile Therapeutics, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 34.8 billion
- 2027 Estimated Market Size: USD 36.47 billion.
- Projected Market Size: USD 60.58 billion by 2036
- Growth Forecast: 5.7% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Contraceptive Devices (Product)
- Emerging Opportunity Segment: Contraceptive Devices (Product)
Market Growth Drivers and Industry Trends
Rising global focus on reproductive health awareness and family planning programs driving adoption
Greater awareness of reproductive health and the importance of informed family planning is contributing to contraceptive drugs and devices market growth by encouraging individuals and couples to consider pregnancy prevention as part of routine healthcare planning. Public health education, reproductive health counseling, and broader discussions around birth spacing are improving awareness of available contraceptive choices and their appropriate use. Healthcare providers are also placing greater emphasis on individualized contraceptive counseling, enabling users to select methods according to reproductive goals, lifestyle considerations, and medical suitability, which supports wider utilization of both pharmaceutical and device-based contraceptive options.
Increasing preference for long-acting reversible contraceptives improving compliance and effectiveness
Growing preference for long-acting reversible contraceptive methods is strengthening the contraceptive drugs and devices market as users increasingly seek options that provide extended pregnancy prevention without requiring frequent daily or monthly adherence. Methods such as intrauterine devices and contraceptive implants can reduce the opportunity for user-related lapses associated with short-acting methods while maintaining reversibility when pregnancy is desired. Healthcare providers are increasingly incorporating these options into contraceptive counseling because their prolonged duration and low dependence on routine user action can support consistent contraceptive use among individuals seeking longer-term pregnancy prevention.
Expanding government-led contraception access initiatives improving affordability in developing regions
Government-supported reproductive health initiatives are helping expand the contraceptive drugs and devices market by improving access to family planning services, particularly in developing and underserved regions. Public-sector programs can strengthen distribution networks, integrate contraceptive services into primary healthcare, and provide education that helps communities understand available methods and their appropriate use. Efforts to reduce financial and geographic barriers are particularly important for populations with limited access to private healthcare services, while broader availability through public health facilities can increase the uptake of contraceptive options across different communities.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global focus on reproductive health awareness and family planning programs driving adoption | 2.30% | High | Asia Pacific, Africa, North America | High | Near Term |
| Increasing preference for long-acting reversible contraceptives improving compliance and effectiveness | 2.00% | High | North America, Europe | High | Mid Term |
| Expanding government-led contraception access initiatives improving affordability in developing regions | 1.80% | High | Asia Pacific, Latin America, Africa | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the largest share of the contraceptive drugs and devices market in 2026, supported by comparatively high awareness of reproductive health, broad availability of contraceptive options, and established healthcare delivery systems. Greater access to family-planning services and increasing emphasis on informed reproductive choices contribute to sustained demand for hormonal contraceptives, long-acting methods, and other preventive solutions. Well-developed clinical infrastructure and greater acceptance of modern contraceptive technologies also facilitate product adoption. Continued attention to reproductive healthcare access and patient-centered contraceptive choices further strengthens the region's market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is expected to register the fastest growth in the contraceptive drugs and devices market, driven by a large reproductive-age population, expanding healthcare access, and increasing awareness of family planning and reproductive health. Improvements in healthcare infrastructure are making contraceptive services more accessible, particularly across developing economies, while public health initiatives are supporting greater awareness of birth spacing and pregnancy prevention. Rising participation of women in education and employment is also contributing to changing family-planning preferences. Increasing availability of modern contraceptive methods and broader acceptance of reproductive healthcare are expected to accelerate market expansion across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Preventive Healthcare IntegrationGermany integrates contraceptive drugs and devices into established reproductive healthcare services with an emphasis on informed clinical guidance. The market supports demand for reliable, evidence-based contraceptive solutions tailored to individual patient needs and long-term reproductive planning.
France 🇫🇷
Public Health AccessibilityFrance supports the contraceptive drugs and devices market through established reproductive health programs and preventive healthcare initiatives. Demand remains focused on accessible contraceptive options, consistent clinical support, and product innovation that enhances patient convenience and adherence.
Italy 🇮🇹
Clinical Care AlignmentItaly emphasizes contraceptive drugs and devices within gynecological care and family planning services. Healthcare providers increasingly recommend personalized contraceptive approaches that balance effectiveness, patient preferences, and long-term reproductive health management.
Japan 🇯🇵
Patient-Centered AdoptionJapan continues expanding awareness and clinical use of modern contraceptive drugs and devices through evolving reproductive healthcare practices. Healthcare professionals focus on improving patient education, treatment suitability, and access to contraceptive options that align with individual preferences.
South Korea 🇰🇷
Expanding Reproductive CareSouth Korea is strengthening access to contraceptive drugs and devices through increasing awareness of reproductive health and preventive care. Market participants prioritize innovative product offerings and patient engagement strategies that support informed contraceptive decision-making across different age groups.
United States 🇺🇸
Comprehensive Product AccessThe U.S. contraceptive drugs and devices market is characterized by broad product availability across prescription and over-the-counter categories. Healthcare providers continue emphasizing patient choice, long-acting contraceptive options, and expanded access through diverse clinical and retail distribution channels.
Segment Leadership and Growth Trends
Contraceptive Drugs and Devices Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Contraceptive Devices (Largest & Fastest-Growing Segment)
The contraceptive devices segment accounted for a 66.54% share of the contraceptive drugs and devices market in 2026 and remained both the largest and fastest-growing product category. Its strong position is supported by demand for contraceptive options that provide reliable pregnancy prevention while reducing dependence on frequent user intervention. Device-based methods can offer extended protection and greater convenience, which is particularly relevant as individuals place greater emphasis on reproductive choice and flexible family-planning options. Increasing awareness of contraceptive alternatives, improvements in product design, and broader access to reproductive healthcare are also supporting adoption. The combination of convenience, effectiveness, and evolving user preferences continues to reinforce the segment's leading position and growth momentum.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Contraceptive Drugs, Contraceptive Devices | Contraceptive Devices | Contraceptive Devices |
Competitive Landscape and Market Positioning
Major players in the contraceptive drugs and devices market:
1. Bayer AG (Germany)
2. Organon & Co. (United States)
3. Pfizer Inc. (United States)
4. AbbVie Inc. (United States)
5. Viatris Inc. (United States)
6. Johnson & Johnson (United States)
7. Church & Dwight Co. Inc. (United States)
8. Veru Inc. (United States)
9. Cupid Limited (India)
10. Agile Therapeutics Inc. (United States)
Growing focus on reproductive healthcare and family planning is reshaping the contraceptive drugs and devices market. Market activity is centered around the development of user-friendly products with improved safety profiles and long-term effectiveness. Continuous innovation in delivery systems and formulations, combined with rising awareness regarding women’s healthcare options, is contributing to broader product adoption and stronger market penetration across multiple demographics.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Bayer AG (Germany) | |||||||
| Organon & Co. (United States) | |||||||
| Pfizer Inc. (United States) | |||||||
| AbbVie Inc. (United States) | |||||||
| Viatris Inc. (United States) | |||||||
| Johnson & Johnson (United States) | |||||||
| Church & Dwight Co. Inc. (United States) | |||||||
| Veru Inc. (United States) | |||||||
| Cupid Limited (India) | |||||||
| Agile Therapeutics Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| China Government | Jan-26 | The Chinese government reinstated a 13% value-added tax on contraceptives and condoms, ending a three-decade-old exemption. This fiscal policy shift is a strategic effort to influence demographic trends and address declining national birth rates by increasing the cost and potentially reducing the accessibility of contraceptive products within the domestic market. |
| NEXT Life Sciences | Mar-25 | NEXT Life Sciences initiated clinical trials in Australia for Plan A, a reversible, non-hormonal male contraceptive system designed to occlude the vas deferens. This advancement represents a significant step in diversifying the male contraceptive landscape, addressing a long-standing market gap for long-acting, reversible options that shift reproductive health responsibility beyond traditional methods. |
| Femasys | Mar-25 | Femasys secured CE mark certification for its FemBloc delivery system, the first non-surgical permanent birth control device. This regulatory milestone provides a less invasive alternative to traditional tubal ligation, enabling in-office procedures that reduce surgical risks and recovery times, thereby expanding access to permanent contraception options in the European market. |
| Daré Bioscience | Feb-25 | Daré Bioscience and Theramex entered a co-development agreement for Casea S, a biodegradable, long-acting contraceptive implant. The device is designed to provide contraception for 18–24 months before dissolving, which eliminates the requirement for surgical removal and addresses a critical usability barrier associated with current long-acting reversible contraceptive implants. |
| Ministry of Population and Family Development Indonesia | Dec-24 | The Indonesian Ministry of Population and Family Development successfully integrated its contraceptive supply information system with national family planning infrastructure. This digital transformation streamlines data management, improves the accuracy of inventory forecasting, and enhances the efficiency of distribution networks to ensure consistent supply chain reliability for contraceptive products across the country. |
| Perrigo | Mar-24 | Perrigo commenced U.S. retail sales of Opill, the first daily oral contraceptive approved for over-the-counter access. By removing the requirement for a medical prescription, this market entry significantly lowers barriers to hormonal contraception, expanding the commercial reach of progestin-only pills to a broader consumer demographic through major retail and online pharmacy channels. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Contraceptive Drugs and Devices Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Contraceptive Method Class | Hormonal Methods, Barrier Methods, Intrauterine Methods, Implantable Methods, Permanent Methods |
| Distribution Channel | Hospital and Clinic Channels, Retail Pharmacies, Online Channels, Public Health and NGO Channels |
| Supply Sector | Public Sector, Private Healthcare Sector, Direct-to-Consumer |
Contraceptive Drugs and Devices Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Family Planning Policy and Funding Landscape |
|
| Unmet Contraceptive Needs and White Space Analysis |
|
| Digital Health and Telemedicine Impact Assessment |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current revenue of the contraceptive drugs and devices market?
What is the projected value of the contraceptive drugs and devices industry by 2036?
How is rising reproductive health awareness influencing contraceptive adoption behavior globally?
How are long-acting contraceptive preferences and government initiatives reshaping market access and usage patterns?
Why do Contraceptive Devices dominate the market?
What is driving growth within Contraceptive Devices?
Why is North America the leading region in the contraceptive drugs and devices market?
What is driving contraceptive market growth in Asia Pacific?
Which companies are driving growth in the contraceptive drugs and devices landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization